Background: Pre-existent immunity and low immunogenicity are major obstacles in vaccine development. Therefore, a great focus in vaccine research is the design of vaccine vectors with low seroprevalence and high immunogenicity. Replication-incompetent lymphocytic choriomeningitis virus (rLCMV) vectors do not elicit vector-neutralizing antibody responses, and homologous prime-boost with rLCMV vectors induces highly boostable and protective OVA-specific T cell responses in mice. However, cellular and humoral immune responses following homologous rLCMV vaccine regimens have not been rigorously evaluated in other infection systems in NHP models. We hypothesized that rLCMV vectors could constitute effective vaccine platforms due to the low seroprevalence of LCMV and its robust induction of immune memory.
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Materials and Methods: C57BL/6 mice and cynomolgus macaques were used for these studies. Immunizations were performed intramuscularly (i.m.) with various doses of rLCMV vectors expressing SIVmac239 Gag and Env antigens. Immune responses were assessed at various time points using ELISA, neutralization assays, ELISPOTs, and multiparameter intracellular cytokine (ICS) assays. Sera or peripheral blood mononuclear cells (PBMCs) were harvested and used for immunological assays.
Results:
We have developed novel rLCMV vectors expressing SIVmac239 Env and Gag antigens, and we have assessed their immunogenicity in mice and cynomolgus macaques. Immunization with rLCMV vaccine vectors expressing SIV Env and Gag were effective at generating SIV-specific T cell responses and Tier 1A neutralizing antibody responses Conclusions: Our results suggest the potential of rLCMV vectors as preclinical prime-boost vaccine regimens. Future SIV challenge experiments in rhesus macaques will ultimately assess immune protection by these vaccine vectors.
